The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Future directions in gastrointestinal cancer
Thorsten O. Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, outlines the changing treatment landscape of patients with gastrointestinal malignancies including combining chemotherapy and immune checkpoint blockade, emerging targeted therapies including the FGFR inhibitor bemarituzumab, as well as HER2-targeting agents in patients with HER2 alternations. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
